Expanding the Druggable Landscape: Targeting Signalling, Cytoskeletal & Chromatin Pathways to Unlock Next-Generation RAS Combination Strategies
- Identifying novel druggable vulnerabilities across signalling, cytoskeletal, and chromatin networks to open new therapeutic opportunities beyond conventional targets
- Targeting protein-protein interactions and defining optimal developmental treatment windows to maximize inhibitor impact while improving translational success
- Leveraging RAC and RAS pathway biology alongside a predictive combination platform to design rational therapies, validated through pioneering brain cancer research and published studies